BACTERIAL LYSATES OF ESCHERICHIA COLI STIMULATE PRODUCTION OF DEFENSINS BY PERIPHERAL BLOOD NEUTROPHILS

Cover Page


Cite item

Full Text

Abstract

Aim. Study effect of a microbial-origin preparation based on Escherichia coli bacteria lysate (Uro-Vaksom) on defensin production (HNP1-3, lactoferrin - LF) and IgM/IgA in patients with recurring infections oflower urinary tract (RILUT). Materials and methods. 40 women with RILUT aged 18 - 68 years, who received monotherapy with Uro-Vaksom (bacterial lysate of 18 E. coli strains), and 26 healthy women were included into the study. Levels of defensins and immunoglobulins in blood were determined using ELISA (HNP1-3, LF, Elisa Kit, Hycult biotech, Netherlands; Serazym Human IgA, IgM, Germany). Rerate. A reduced level of defensins HNP1-3 and LF was noted in patients with RILUT, that gives evidence on chronical course of the inflammatory process on the organism. Use of E. coli lysate resulted in normalization of these parameters in blood sera of women. IgM and IgA levels in blood of the patients remained within normal values, and use of the bacterial lysate did not affect them. Conclusion. Use of Uro-Vaksom based on E. coli bacteria lysate has immune-correcting effect during therapy of patients with RILUT.

About the authors

N. K. Akhmatova

Mechnikov Research Institute of Vaccines and Sera

Author for correspondence.
Email: noemail@neicon.ru
Russian Federation

V. G. Khomenkov

Mechnikov Research Institute of Vaccines and Sera

Email: noemail@neicon.ru
Russian Federation

E. V. Volkova

Research Institute of Urology and Intervention Radiology

Email: noemail@neicon.ru
Russian Federation

E. A. Akhmatova

Mechnikov Research Institute of Vaccines and Sera; Sechenov First Moscow State Medical University

Email: noemail@neicon.ru
Russian Federation

I. A. Semochkin

Mechnikov Research Institute of Vaccines and Sera

Email: noemail@neicon.ru
Russian Federation

T. S. Perepanova

Research Institute of Urology and Intervention Radiology

Email: noemail@neicon.ru
Russian Federation

V. V. Zverev

Mechnikov Research Institute of Vaccines and Sera; Sechenov First Moscow State Medical University

Email: noemail@neicon.ru
Russian Federation

References

  1. Bessler W.G., vor dem Esche U., Zgaga-Griesz A. et al. Immunostimulatory properties of the bacterial extract OM-89 in vitro and in vivo. Arzneimittelforschung. 2010, 60 (6): 324-329.
  2. Breakey A. A, Hinde K., Valeggia C.R. et al. Illness in breastfeeding infants relates to concentration of lactoferrin and secretory immunoglobulin A in mother's milk. Evol. Med. Public. Health. 2015, 20(1): 21-31.
  3. Brusca I. Overview of biomarkers for diagnosis and monitoring of celiac disease. Adv. Clin. Chem. 2015,68: 1-55.
  4. Gibbins H.L, Proctor G. B., Yakubov G.E. et al. SIgA binding to mucosal surfaces is mediated by mucin-mucin interactions. PLoS One. 2015, 20; 10 (3): eOl 19677.
  5. Gupta I., Sehgal R., Kanwar R.K. et al. Nanocapsules loaded with iron-saturated bovine lactoferrin have antimicrobial therapeutic potential and maintain calcium, zinc and iron metabolism. Nanomedicine (Lond). 2014, 2: 1-26.
  6. Hao J., Wang C., Yuan J. et al. A pro-inflammatory role of C5L2 in C5a-primed neutrophils for ANCA-induced activation. PLoS One. 2013, 13; 8 (6): e66305.
  7. Koning N., Kessen S.F., Van Der Voorn J.P. et al. Human milk blocks DC-SIGN-pathogen interaction via MUC1. Front. Immunol. 2015, 13; 6: 112.
  8. Lehmann F.S., Burri E., Beglinger C. The role and utility of faecal markers in-inflammatory bowel disease. Therap. Adv. Gastroenterol. 2015, 8 (1): 23-36.
  9. PandaS., DingJ.L. Natural antibodies bridge innate and adaptive immunity. J. Immunol. 2015, 1; 194(1): 13-20.
  10. Yamamoto T. The clinical value of faecal calprotectin and lactoferrin measurement in postoperative Crohn's disease. United European Gastroenterol. J. 2015, 3 (1): 5-10.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2016 Akhmatova N.K., Khomenkov V.G., Volkova E.V., Akhmatova E.A., Semochkin I.A., Perepanova T.S., Zverev V.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС77-75442 от 01.04.2019 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies